LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the signing of a partnership with WhiteLab Genomics (WLG), a Paris and Boston-based biotech company specializing in Artificial Intelligence for Genomic Medicine R&D.

瑞士洛桑--（商业新闻短讯）--Debiopharm是一家总部位于瑞士的私营生物制药公司，旨在建立未来治疗癌症和传染病的标准，今天宣布与WhiteLab Genomics（WLG）签署合作伙伴关系，这是一家总部位于巴黎和波士顿的生物技术公司，专门从事基因组医学研发的人工智能。

This collaboration aims to achieve two key objectives. The first is to identify cancer-specific receptors that are overexpressed on the surface of cancer cells. The second is to find lead candidates capable of binding to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles (LNPs) to enhance active tissue targeting.

这种合作旨在实现两个关键目标。首先是鉴定在癌细胞表面过表达的癌症特异性受体。第二个是寻找能够与这些受体结合的先导候选物。一旦确定，这些药物将附着在脂质纳米颗粒（LNPs）的表面以增强活性组织靶向。

Lipid nanoparticles (LNPs) have emerged as a gold standard vector for drug delivery with the potential to transform the oncology landscape, particularly the genomic medicine field, through their high delivery efficacy. One of the challenges with LNPs is their tendency to accumulate in non-target organs like the liver, which limits their distribution to the desired site.

脂质纳米颗粒（LNPs）已成为药物递送的金标准载体，具有通过其高递送功效改变肿瘤学景观，特别是基因组医学领域的潜力。LNPs的挑战之一是它们倾向于在肝脏等非靶器官中积累，这限制了它们在所需部位的分布。

To maximize LNPs potential, WLG is set to deploy its AI-powered platform to explore innovative in silico approaches for enhancing the targeted delivery capabilities of LNPs, creating new opportunities for therapeutic applications..

为了最大限度地发挥LNPs的潜力，WLG将部署其人工智能平台，探索创新的计算机方法，以增强LNPs的目标交付能力，为治疗应用创造新的机会。。

As a key investor in WLG, Debiopharm has consistently supported the company's innovative approaches and cutting-edge solutions through Debiopharm’s Innovation Fund. This collaboration provides a significant opportunity to validate the potential of WLG’s AI platform and strengthen their ongoing relationship..

作为WLG的主要投资者，Debiopharm一直通过Debiopharm的创新基金支持公司的创新方法和前沿解决方案。这种合作为验证WLG人工智能平台的潜力和加强他们之间的持续关系提供了重要机会。。

'WhiteLab’s innovative AI platform represents a significant advancement in the field of targeted cancer therapy. By improving the specificity and delivery of lipid nanoparticles, we aim to provide more effective treatments for patients suffering from hormonal cancers,' said David Del Bourgo, CEO co-founder of WLG.

“WhiteLab的创新AI平台代表了靶向癌症治疗领域的重大进步。WLG首席执行官联合创始人大卫·德尔·博格（DavidDelBourgo）说，通过提高脂质纳米颗粒的特异性和递送性，我们的目标是为患有激素性癌症的患者提供更有效的治疗。

'Our collaboration with a leading player such as Debiopharm further demonstrates our focus on developing cutting-edge solutions that have the potential to transform cancer treatments.'.

“我们与Debiopharm等领先厂商的合作进一步证明了我们专注于开发有可能改变癌症治疗方法的尖端解决方案。”。

“As a company specialized in drug development, we know the hardships of the field and therefore we recognize the added value of AI powered platforms like the WhiteLab Genomics’ platform applied to the early stages of drugs R&D. We look forward to fully exploiting the potential of AI based solutions to develop drugs, de-risk assets, de-risk any toxicity, and ensure that we bring the most efficacious and personalized drugs to patients.” said Betrand Ducrey, CEO of Debiopharm.

Debiopharm首席执行官Betrand Ducrey说：“作为一家专门从事药物开发的公司，我们了解该领域的困难，因此我们认识到应用于药物研发早期阶段的WhiteLab Genomics平台等人工智能平台的附加价值。我们期待着充分利用基于人工智能的解决方案的潜力，开发药物，降低风险资产，降低任何毒性风险，并确保我们为患者带来最有效和个性化的药物。”。

About WhiteLab Genomics

关于WhiteLab Genomics

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks.

WhiteLab Genomics成立于2019年，由Y-Combinator支持，致力于计算机科学和生物学的融合，开创了基因组药物的加速发展。通过利用其专有技术，WhiteLab Genomics分析了人工智能支持的复杂生物数据，以显着缩短开发时间表并减轻相关风险。

Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies.

该平台基于详尽的数据集，提供计算机模拟，以发现和设计优化的有效载荷和向量。WhiteLab旨在加快药物开发过程，降低成本，并加速向市场提供挽救生命的疗法。该公司与赛诺菲（Sanofi）、学术机构和创新生物技术公司等领先制药公司合作。

Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks' Technology Network, marking major milestones in our international expansion..

WhiteLab Genomics因其对推进基因和细胞治疗领域的贡献而受到认可，它是著名的法国政府支持的法国科技2030计划的一部分，最近加入了位于马萨诸塞州剑桥的拜耳公司实验室和银杏生物工程技术网络，标志着我们国际扩张的重大里程碑。。

Visit us https://whitelabgx.com/

Visit us https://whitelabgx.com/

Follow us on LinkedIn

在LinkedIn上关注我们

About Debiopharm

关于Debiopharm

Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally..

Debiopharm开发了针对肿瘤学和传染病中高度未满足的医疗需求的创新疗法。弥合破坏性发现产品与国际患者覆盖范围之间的差距，我们确定了用于许可的高潜力化合物和技术，临床证明了它们的安全性和有效性，然后选择了大型药物商业化合作伙伴，以最大限度地提高全球患者的可及性。。

Visit us www.debiopharm.com

访问我们www.debiopharm.com

Follow us on X @DebiopharmNews at http://twitter.com/DebiopharmNews

在X@DebiopharmNews上关注我们http://twitter.com/DebiopharmNews

Follow us on LinkedIn

在LinkedIn上关注我们

About Debiopharm Innovation Fund

关于Debiopharm创新基金

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds.

Debiopharm创新基金是瑞士生物制药公司Debiopharm的战略投资部门，为有志于改善患者旅程和改变药物研发的公司提供资金和指导。自2017年以来，Debiopharm投资了15家人工智能和数字健康公司，通常是领先的投资回合。

As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity..

。。

For more information, please visit www.debiopharm.com/innovation-fund/

/

To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/

要了解有关投资标准的更多信息，请访问https://www.debiopharm.com/innovation-fund/approach/